<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04144517</url>
  </required_header>
  <id_info>
    <org_study_id>ION-01-ALKS 4230</org_study_id>
    <nct_id>NCT04144517</nct_id>
  </id_info>
  <brief_title>A Study of ALKS 4230 (Nemvaleukin Alfa) With Pembrolizumab in Head and Neck Cancer</brief_title>
  <official_title>A Phase 2 Study of ALKS 4230 in Combination With Anti-PD-1 (Pembrolizumab) in Patients With Advanced or Recurrent Head and Neck Squamous Cell Cancer Currently on Treatment With Anti-PD-(L)1 Without Having Achieved a Complete Remission</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alkermes, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Immune Oncology Network</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Alkermes, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to estimate the response rate to ALKS 4230 in&#xD;
      combination with pembrolizumab in patients with HNSCC who have previously received&#xD;
      anti-PD-(L)1 therapy but who have not achieved a CR.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">February 5, 2020</start_date>
  <completion_date type="Anticipated">October 2022</completion_date>
  <primary_completion_date type="Actual">October 8, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of patients with objective evidence of improvement to partial response among those patients who had stable disease at baseline on prior anti-PD-(L)1 therapy</measure>
    <time_frame>From time of initiation of therapy until the date of first documented tumor progression, assessed up to 12 months</time_frame>
    <description>Response will be based on investigator review of radiographic and/or photographic images and RECIST criteria v1.1</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of patients with objective evidence of improvement to complete response among those patients who had stable disease or partial response at baseline on prior anti-PD-(L)1 therapy</measure>
    <time_frame>From time of initiation of therapy until the date of first documented tumor progression, assessed up to 12 months</time_frame>
    <description>Response will be based on investigator review of radiographic and/or photographic images and RECIST criteria v1.1</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of patients with objective evidence of improvement to partial response among those patients who had disease progression at baseline on prior anti-PD-(L)1 therapy</measure>
    <time_frame>From time of initiation of therapy until the date of first documented tumor progression, assessed up to 12 months</time_frame>
    <description>Response will be based on investigator review of radiographic and/or photographic images and RECIST criteria v1.1</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of patients with objective evidence of improvement to complete response among those patients who had disease progression at baseline on prior anti-PD-(L)1 therapy</measure>
    <time_frame>From time of initiation of therapy until the date of first documented tumor progression, assessed up to 12 months</time_frame>
    <description>Response will be based on investigator review of radiographic and/or photographic images and RECIST criteria v1.1</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration of response in subjects with CR or PR</measure>
    <time_frame>Time from the first documentation of complete response or partial response, measured approximately every 6 weeks, to the first documentation of objective tumor progression or death due to any cause (estimated up to 24 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>Time from first dose of study drug to the time of first documentation of objective tumor progression or death due to any cause (estimated up to 24 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to progression</measure>
    <time_frame>Time from first dose of study drug to the time of first documentation of objective tumor progression or death due to disease progression (estimated up to 24 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of non-progression (ie, disease control rate) at 6 months</measure>
    <time_frame>Assessed PFS at 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>Time from first dose of study drug to the time of death (estimated up to 24 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of drug-related AEs</measure>
    <time_frame>Time from first dose of study drug to the end of study (up to 36 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of drug-related SAEs</measure>
    <time_frame>Time from first dose of study drug to the end of study (up to 36 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of drug-related AEs leading to discontinuation</measure>
    <time_frame>Time from first dose of study drug to the end of study (up to 36 months)</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">14</enrollment>
  <condition>Non-cutaneous Squamous Cell Carcinoma of Head and Neck</condition>
  <arm_group>
    <arm_group_label>ALKS 4230 + pembrolizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ALKS 4230</intervention_name>
    <description>Intravenous (IV) infusion over 30 minutes given daily for 5 consecutive days followed by an off-treatment period</description>
    <arm_group_label>ALKS 4230 + pembrolizumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pembrolizumab</intervention_name>
    <description>IV infusion over 30 minutes administered on Day 1 of each cycle</description>
    <arm_group_label>ALKS 4230 + pembrolizumab</arm_group_label>
    <other_name>Keytruda</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients must have histologically or cytopathologically confirmed diagnosis of&#xD;
             non-cutaneous squamous cell carcinoma of the head and neck region that is locally&#xD;
             advanced and/or recurrent and no longer amenable to local surgical or radiation&#xD;
             therapy and/or with evidence of distant metastatic disease&#xD;
&#xD;
          -  Patients must have had anti-PD-(L)1 therapy as the most recent systemic therapy with&#xD;
             either stable disease or partial response on prior anti-PD-(L)1 therapy, or&#xD;
             progressive disease on prior anti-PD-(L)1 therapy&#xD;
&#xD;
          -  Patients must have disease that is measurable by RECIST v1.1&#xD;
&#xD;
          -  Patients must be willing to provide tumor tissue biopsy&#xD;
&#xD;
          -  Patients must demonstrate adequate organ function&#xD;
&#xD;
          -  Female patients of childbearing potential should have a negative pregnancy test within&#xD;
             72 hours prior to receiving the first dose of study medication&#xD;
&#xD;
          -  Patients must agree to follow contraceptive requirements defined in the protocol&#xD;
&#xD;
          -  Additional criteria apply&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient is pregnant or breastfeeding or expecting to conceive or father children&#xD;
&#xD;
          -  Patient has an active major infection requiring systemic therapy within 1 week of&#xD;
             starting study drug&#xD;
&#xD;
          -  Patient has known active central nervous system (CNS) metastases and/or carcinomatous&#xD;
             meningitis. Patients with previously treated brain metastases may participate,&#xD;
             provided that they are stable, have no evidence of new or enlarging brain metastases,&#xD;
             and are not using steroids for at least 7 days prior to study drug&#xD;
&#xD;
          -  Patient has hypersensitivity to pembrolizumab, ALKS 4230, or any of their excipients&#xD;
&#xD;
          -  Patient has a diagnosis of immunodeficiency or is receiving systemic steroid therapy&#xD;
             (inhaled or topical steroids and steroid replacement at physiologic doses are&#xD;
             allowable)&#xD;
&#xD;
          -  Patient has prior Grade â‰¥3 immune-related toxicities requiring systemic&#xD;
             immunosuppressant treatment that were attributable or possibly attributable to PD-1&#xD;
             immune checkpoint blockade&#xD;
&#xD;
          -  Patient has active tuberculosis or known active infection with hepatitis B or&#xD;
             hepatitis C&#xD;
&#xD;
          -  Patient has known psychiatric or substance abuse disorders or a social situation that&#xD;
             would interfere with cooperation with the requirements of the study&#xD;
&#xD;
          -  Additional criteria apply&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Timothy Leach, MD</last_name>
    <role>Study Director</role>
    <affiliation>Alkermes, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Alkermes Investigational Site</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alkermes Investigational Site</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30308</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alkermes Investigational Site</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alkermes Investigational Site</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alkermes Investigational Site</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alkermes Investigational Site</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78712</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 24, 2019</study_first_submitted>
  <study_first_submitted_qc>October 28, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 30, 2019</study_first_posted>
  <last_update_submitted>October 20, 2021</last_update_submitted>
  <last_update_submitted_qc>October 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Alkermes</keyword>
  <keyword>IL-2</keyword>
  <keyword>Interleukin-2</keyword>
  <keyword>Oncology</keyword>
  <keyword>Immuno-oncology</keyword>
  <keyword>Cytokine Immunotherapy</keyword>
  <keyword>ALKS 4230</keyword>
  <keyword>Pembrolizumab</keyword>
  <keyword>Keytruda</keyword>
  <keyword>PD-L1</keyword>
  <keyword>Solid Tumors</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Squamous Cell Carcinoma of Head and Neck</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pembrolizumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

